Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30 - Earnings Summary

• Arcturus Therapeutics Holdings Inc ARCT.OQ reported a quarterly adjusted loss of 34 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -64 cents. The mean expectation of eleven analysts for the quarter was for a loss of 89 cents per share. Wall Street expected results to range from $-1.76 to -34 cents per share.

• Revenue fell 43.2% to $28.30 million from a year ago; analysts expected $23.05 million.

• Arcturus Therapeutics Holdings Inc's reported EPS for the quarter was a loss of 34 cents​.

• The company reported a quarterly loss of $9.18 million.

• Arcturus Therapeutics Holdings Inc shares had fallen by 8.5% this quarter and lost 29.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 17.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Arcturus Therapeutics Holdings Inc is $54.00, about 77.9% above its last closing price of $11.91

This summary was machine generated from LSEG data August 11 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)